Reverse engineering of BNIP3 identifies a mitochondrial protective peptide

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Mitochondria are crucial in disease, but drug development faces challenges due to poor understanding of cell death regulators.
• The BH3-only protein BNIP3 is implicated in mitochondrial cell death pathways.

Purpose of the Study:

• To elucidate the upstream molecular regulators of mitochondrial fate.
• To identify and characterize the functional domain of BNIP3 responsible for activating cell death.
• To develop a therapeutic agent targeting BNIP3-mediated mitochondrial cell death.

Main Methods:

• Structural modeling and sequence-function analysis of BNIP3's N-terminus.
• Development of a BNIP3 antagonist peptide (B-017).
• In vitro assays using human cells and in vivo studies in animal models (heart, brain, liver).

Main Results:

• Identified a critical functional domain and amino acid hotspots in BNIP3's N-terminus that activate BCL-2 executioner proteins.
• Developed B-017, a peptide that specifically inhibits BNIP3-BCL-2 interactions, preserving mitochondrial integrity.
• B-017 showed target specificity, a good safety profile, suppressed cell death signaling, and reduced tissue damage in animal models.

Conclusions:

• BNIP3 is a key activator of mitochondrial cell death through BCL-2 protein interaction.
• B-017 is a potent and specific therapeutic candidate for diseases involving mitochondrial dysfunction.
• Targeting BNIP3 offers a promising strategy to mitigate tissue damage in various clinical conditions.